# Accelerated Fractionated Radiation Therapy for Localized Glottic Carcinoma

## TL;DR

This study shows that accelerated radiation therapy for early-stage glottic cancer is effective with high local control and minimal recurrence.

## Contribution

The study introduces an accelerated fractionated radiation approach for N0 glottic carcinoma with favorable outcomes.

## Key findings

- A 3-year local control rate of 95.6% was achieved with accelerated fractionated irradiation.
- No lymph node or distant recurrences were observed in the patient cohort.
- Acute dermatitis and mucositis were common, but late adverse events were rare.

## Abstract

Background: The aim of this study is to examine the outcomes of an accelerated fractionated irradiation for N0 glottic carcinoma. Methods: In this retrospective analysis, 29 patients with N0 glottic carcinoma treated by radiation therapy were enrolled. Thirteen patients had T1a disease, six had T1b disease, and ten had T2 disease. A fractional dose of 2.1 Gy was administered to seven patients. The total doses were 65.1 and 67.2 Gy in four and three patients, respectively. A fractional dose of 2.25 Gy was administered to 22 patients. The total doses were 63 and 67.5 Gy in 21 patients and 1 patient with T2 disease, respectively. Additionally, 13 patients underwent the use of TS-1 (80–100 mg per day). Results: The median follow-up period was 33 months, and the 3-year local control rate was 95.6%. No patient had a lymph node or distant recurrence. As acute adverse events, grades 2 and 3 dermatitis were observed in 18 patients and 1 patient, and grades 2 and 3 mucositis were observed in 15 patients and 1 patient. As a late adverse event, one patient required tracheotomy because of laryngeal edema occurring. Conclusions: Accelerated fractionated irradiation may be an option in the radiation therapy of N0 glottic carcinoma because of its ability to shorten the treatment time.